Serum tumor marker use in patients with advanced solid tumors

Journal of Oncology Practice

Volumn 12, Issue 1, 2016, Pages e36-e43

  Accordino, Melissa K ^a   Wright, Jason D ^a   Vasan, Sowmya ^a   Neugut, Alfred I ^a   Tergas, Ana ^a   Hu, Jim C ^a   Hershman, Dawn L ^a  

^a

^b United States

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE DURATION; FEMALE; HUMAN; ICD-9; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT CARE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SOLID TUMOR; BLOOD; HEALTH SERVICE; NEOPLASMS; PROGNOSIS;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; MEDICAL OVERUSE; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84958576458     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.005660     Document Type: Article

References (47)

1. National Cancer Data Base Public Benchmark Reports: Cases diagnosed 2000- 2011. http://cromwell.facs.org/BMarks/BMPub/Ver10/bm-reports.cfm
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 1.2015. www.nccn.org/professionals/physician-gls/pdf/breast.pdf
3. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
4. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
5. Virji MA, Mercer DW, Herberman RB: Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin 38:104-126, 1988
6. NationalCancer Institute: FactSheet: Tumormarkers.www.cancer.gov/cancertopics/factsheet/detection/tumor-markers
7. Perkins GL, Slater ED, Sanders GK, et al: Serum tumor markers. Am Fam Physician 68:1075-1082, 2003
8. National Comprehensive Cancer Network: NCCN Clinical Guideline in Oncology: Hepatobiliary Cancers Version 2.2015. www.nccn.org/professionals/physician-gls/pdf/hepatobiliary.pdf
9. Ballehaninna UK, Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105-119, 2012
10. Strom BL, Maislin G, West SL, et al: Serum CEA and CA 19-9: Potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer 45:821-824, 1990
11. Cheung KL, Graves CR, Robertson JF: Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91-102, 2000
12. Farinati F, MarinoD, De Giorgio M, et al: Diagnostic and prognostic role of alphafetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol 101: 524-532, 2006
13. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 1.2015. www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf
14. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
15. Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 376:1155-1163, 2010
16. Smerage JB, Barlow WE, Hortobagyi GN, et al: Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-3489, 2014
17. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
18. Schnipper LE, Lyman GH, Blayney DW, et al: American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 31:4362-4370, 2013
19. Berwick DM, Hackbarth AD: Eliminating waste in US health care. JAMA 307: 1513-1516, 2012
20. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2015. www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf
21. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 2.2015. www.nccn.org/professionals/physician-gls/pdf/colon.pdf
22. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 2.2015. www.nccn.org/professionals/physician-gls/pdf/rectal.pdf
23. Grunnet M, Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138-143, 2012
24. Rodríguez-Moranta F, Saló J, Arcusa A, et al: Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:386-393, 2006
25. Guyot F, Faivre J, Manfredi S, et al: Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 16:756-761, 2005
26. Secco GB, Fardelli R, Gianquinto D, et al: Efficacy and cost of risk-adapted followup in patients after colorectal cancer surgery: A prospective, randomized and controlled trial. Eur J Surg Oncol 28:418-423, 2002
27. Jeffery M, Hickey BE, Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 1:CD002200, 2007
28. Renehan AG, Egger M, Saunders MP, et al: Impact on survival of intensive follow up after curative resection for colorectal cancer: Systematic review and metaanalysis of randomised trials. BMJ 324:813, 2002
29. Tsikitis VL, Malireddy K, Green EA, et al: Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 27:3671-3676, 2009
30. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001
31. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer Version 4.015. www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
32. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer Version 1.2015. www.nccn.org/professionals/physician-gls/pdf/sclc.pdf
33. Merimsky O, Kovner F, Inbar M, et al: Tamoxifen for disease-negative but MCApositive breast cancer patients. Oncol Rep 4:843-847, 1997
34. Centers for Medicare and Medicaid Services: Medicare Clinical Laboratory Fee Schedule. www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html
35. Sandler RS, Freund DA, Herbst CA Jr, et al: Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer. Cancer 53:193-198, 1984
36. Kievit J, van de Velde CJ: Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation: A Markov analysis. Cancer 65: 2580-2587, 1990
37. Armstrong A, Otvos B, Singh S, et al: Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 131:503-507, 2013
38. Norum J, Olsen JA: A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 8:1081-1087, 1997
39. Graham RA, Wang S, Catalano PJ, et al: Postsurgical surveillance of colon cancer: Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 228:59-63, 1998
40. Tzeng CW, Abbott DE, Cantor SB, et al: Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: A cost-effectiveness analysis. Ann Surg Oncol 20:2197-2203, 2013
41. Ramsey SD, Henry NL, Gralow JR, et al: Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol 33:149-155, 2015
42. Johnston DL, Alonzo TA, Gerbing RB, et al: Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 23: 9172-9178, 2005
43. Hu CY, Bailey CE, You YN, et al: Time trend analysis of primary tumor resection for stage IV colorectal cancer: Less surgery, improved survival. JAMA Surg 150: 245-251, 2015
44. Buzdar A, Hunt K, Buchholz TA, et al: Improving survival of patients with breast cancer over the past 6 decades: The University of Texas M.D. Anderson Cancer Center experience. Presented at the Breast Cancer Symposium, Washington, DC, October 30, 2010 (abstr 176)
45. American Cancer Society: Breast Cancer Facts and Figures 2011-2012. Atlanta, GA, American Cancer Society, 2011
46. American Cancer Society: Breast Cancer Facts and Figures 2013-2014. Atlanta, GA, American Cancer Society, 2013
47. US Food and Drug Administration: Overview of in vitro diagnostic product regulation. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm